Skip to content


Pomalidomide, a potent medication, operates by binding to CRBN (Cereblon), a crucial component in the cell’s protein degradation pathway. This interaction leads to the degradation of specific protein substrates involved in cancer cell proliferation and survival. As a result, pomalidomide exhibits strong anti-cancer activity, particularly against multiple myeloma and other hematologic malignancies. Its ability to target resistant cancer cells makes it a promising option in overcoming treatment resistance and improving patient outcomes.